HK1232163A1 - 用於抑制α- 抗胰蛋白酶基因表達的組合物及方法 - Google Patents
用於抑制α- 抗胰蛋白酶基因表達的組合物及方法Info
- Publication number
- HK1232163A1 HK1232163A1 HK17106007.9A HK17106007A HK1232163A1 HK 1232163 A1 HK1232163 A1 HK 1232163A1 HK 17106007 A HK17106007 A HK 17106007A HK 1232163 A1 HK1232163 A1 HK 1232163A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- antitrypsin
- alpha
- compositions
- methods
- gene expression
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462013288P | 2014-06-17 | 2014-06-17 | |
PCT/US2015/035976 WO2015195628A2 (en) | 2014-06-17 | 2015-06-16 | Compositions and methods for inhibiting gene expression of alpha-1 antitrypsin |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1232163A1 true HK1232163A1 (zh) | 2018-01-05 |
Family
ID=54835647
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK17106007.9A HK1232163A1 (zh) | 2014-06-17 | 2017-06-16 | 用於抑制α- 抗胰蛋白酶基因表達的組合物及方法 |
Country Status (13)
Country | Link |
---|---|
US (4) | US10006025B2 (zh) |
EP (1) | EP3157541A4 (zh) |
CN (2) | CN106535917B (zh) |
AR (1) | AR100840A1 (zh) |
AU (2) | AU2015277376B2 (zh) |
BR (1) | BR112016029781A2 (zh) |
CA (2) | CA3219720A1 (zh) |
EA (1) | EA201692318A1 (zh) |
HK (1) | HK1232163A1 (zh) |
IL (1) | IL249597A0 (zh) |
MX (3) | MX2016015870A (zh) |
TW (1) | TW201620526A (zh) |
WO (1) | WO2015195628A2 (zh) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011091065A2 (en) | 2010-01-19 | 2011-07-28 | Northwestern University | Synthetic nanostructures including nucleic acids and/or other entities |
CA2919268C (en) | 2013-07-25 | 2023-09-05 | Exicure, Inc. | Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use |
WO2015187966A1 (en) | 2014-06-04 | 2015-12-10 | Aurasense Therapeutics, Llc | Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications |
TW201620526A (zh) * | 2014-06-17 | 2016-06-16 | 愛羅海德研究公司 | 用於抑制α-1抗胰蛋白酶基因表現之組合物及方法 |
CN107002081A (zh) | 2014-10-06 | 2017-08-01 | 埃克西奎雷股份有限公司 | 抗tnf化合物 |
ES2747842T3 (es) * | 2014-12-15 | 2020-03-11 | Dicerna Pharmaceuticals Inc | Acidos nucleicos de doble hebra modificados por ligando |
WO2017139616A1 (en) * | 2016-02-10 | 2017-08-17 | Arrowhead Pharmaceuticals, Inc. | Methods of treatment for alpha-1 antitrypsin deficiency |
AU2017229469B2 (en) | 2016-03-07 | 2023-02-23 | Arrowhead Pharmaceuticals, Inc. | Targeting ligands for therapeutic compounds |
WO2017193087A1 (en) * | 2016-05-06 | 2017-11-09 | Exicure, Inc. | Liposomal spherical nucleic acid (sna) constructs prsenting antisense oligonucleotides(aso) for specific knockdown of interleukin 17 receptor mrna |
WO2018039629A2 (en) | 2016-08-25 | 2018-03-01 | Northwestern University | Micellar spherical nucleic acids from thermoresponsive, traceless templates |
BR112019004178A2 (pt) | 2016-09-02 | 2019-05-28 | Arrowhead Pharmaceuticals Inc | ligantes de alvejamento |
EP3548005A4 (en) | 2016-11-29 | 2020-06-17 | Puretech Health LLC | EXOSOMES FOR THE ADMINISTRATION OF THERAPEUTIC AGENTS |
TWI826365B (zh) | 2017-01-10 | 2023-12-21 | 美商愛羅海德製藥公司 | α-1抗胰蛋白酶 (AAT) RNAi 藥劑、包含AAT RNAi 藥劑之組合物及使用方法 |
US11696954B2 (en) | 2017-04-28 | 2023-07-11 | Exicure Operating Company | Synthesis of spherical nucleic acids using lipophilic moieties |
SE540888C2 (en) * | 2017-06-19 | 2018-12-11 | Hepgene Medical Ab | Novel nucleic acid molecules and their use in therapy |
KR20220019255A (ko) * | 2019-06-06 | 2022-02-16 | 애로우헤드 파마슈티컬스 인코포레이티드 | 알파-1 항트립신 결핍증 (aatd)의 치료 방법 |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3687808A (en) | 1969-08-14 | 1972-08-29 | Univ Leland Stanford Junior | Synthetic polynucleotides |
US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
NZ225176A (en) | 1987-06-24 | 1990-09-26 | Florey Howard Inst | Nucleoside derivatives |
IE61148B1 (en) * | 1988-03-10 | 1994-10-05 | Ici Plc | Method of detecting nucleotide sequences |
US5134066A (en) | 1989-08-29 | 1992-07-28 | Monsanto Company | Improved probes using nucleosides containing 3-dezauracil analogs |
US5591722A (en) | 1989-09-15 | 1997-01-07 | Southern Research Institute | 2'-deoxy-4'-thioribonucleosides and their antiviral activity |
EP0942000B1 (en) | 1989-10-24 | 2004-06-23 | Isis Pharmaceuticals, Inc. | 2'-Modified oligonucleotides |
US5646265A (en) | 1990-01-11 | 1997-07-08 | Isis Pharmceuticals, Inc. | Process for the preparation of 2'-O-alkyl purine phosphoramidites |
US5459255A (en) | 1990-01-11 | 1995-10-17 | Isis Pharmaceuticals, Inc. | N-2 substituted purines |
US5587361A (en) | 1991-10-15 | 1996-12-24 | Isis Pharmaceuticals, Inc. | Oligonucleotides having phosphorothioate linkages of high chiral purity |
US5212295A (en) | 1990-01-11 | 1993-05-18 | Isis Pharmaceuticals | Monomers for preparation of oligonucleotides having chiral phosphorus linkages |
US5489677A (en) | 1990-07-27 | 1996-02-06 | Isis Pharmaceuticals, Inc. | Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms |
US5602240A (en) | 1990-07-27 | 1997-02-11 | Ciba Geigy Ag. | Backbone modified oligonucleotide analogs |
US5539082A (en) | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
CA2122030C (en) | 1991-10-24 | 1997-03-04 | Muthiah Manoharan | Derivatized oligonucleotides having improved uptake and other properties |
US5594121A (en) | 1991-11-07 | 1997-01-14 | Gilead Sciences, Inc. | Enhanced triple-helix and double-helix formation with oligomers containing modified purines |
US5359044A (en) | 1991-12-13 | 1994-10-25 | Isis Pharmaceuticals | Cyclobutyl oligonucleotide surrogates |
EP0577558A2 (de) | 1992-07-01 | 1994-01-05 | Ciba-Geigy Ag | Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte |
NL9201440A (nl) | 1992-08-11 | 1994-03-01 | Univ Leiden | Triantennaire clusterglycosiden, hun bereiding en toepassing. |
US5519134A (en) | 1994-01-11 | 1996-05-21 | Isis Pharmaceuticals, Inc. | Pyrrolidine-containing monomers and oligomers |
US5596091A (en) | 1994-03-18 | 1997-01-21 | The Regents Of The University Of California | Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides |
US5597909A (en) | 1994-08-25 | 1997-01-28 | Chiron Corporation | Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use |
US6172209B1 (en) | 1997-02-14 | 2001-01-09 | Isis Pharmaceuticals Inc. | Aminooxy-modified oligonucleotides and methods for making same |
JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
DE04020014T1 (de) | 1997-09-12 | 2006-01-26 | Exiqon A/S | Bi-zyklische - Nukleosid,Nnukleotid und Oligonukleotid-Analoga |
FR2774379B1 (fr) | 1998-01-30 | 2002-03-29 | Groupe Limagrain Holding | Procede de production, par des cellules vegetales, d'alpha 1-antitrypsine et de ses variantes, et produits contenant l'alpha-antitrypsine ainsi obtenue |
US6271358B1 (en) | 1998-07-27 | 2001-08-07 | Isis Pharmaceuticals, Inc. | RNA targeted 2′-modified oligonucleotides that are conformationally preorganized |
IL144338A0 (en) | 1999-02-12 | 2002-05-23 | Sankyo Co | Nucleoside and oligonucleotide analogues and pharmaceutical compositions containing the same |
AU767195B2 (en) | 1999-03-10 | 2003-11-06 | Phogen Limited | Delivery of substances to cells |
US20050137153A1 (en) * | 2002-02-20 | 2005-06-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of alpha-1 antitrypsin (AAT) gene expression using short interfering nucleic acid (siNA) |
US8090542B2 (en) | 2002-11-14 | 2012-01-03 | Dharmacon Inc. | Functional and hyperfunctional siRNA |
US8653252B2 (en) | 2003-03-21 | 2014-02-18 | Santaris Pharma A/S | Short interfering RNA (siRNA) analogues |
WO2005089287A2 (en) | 2004-03-15 | 2005-09-29 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded rna |
CN101500548A (zh) | 2006-08-18 | 2009-08-05 | 弗·哈夫曼-拉罗切有限公司 | 用于体内递送多核苷酸的多缀合物 |
CN104480112B (zh) | 2007-05-22 | 2018-06-12 | 阿克丘勒斯治疗公司 | 用于治疗的una寡聚体 |
JP2011517404A (ja) * | 2008-03-20 | 2011-06-09 | クォーク・ファーマシューティカルズ・インク | RTP801を阻害するための新規なsiRNA化合物 |
WO2010080129A2 (en) | 2008-12-18 | 2010-07-15 | Dicerna Pharmaceuticals, Inc. | Extended dicer substrate agents and methods for the specific inhibition of gene expression |
WO2010093788A2 (en) | 2009-02-11 | 2010-08-19 | Dicerna Pharmaceuticals, Inc. | Multiplex dicer substrate rna interference molecules having joining sequences |
ES2562817T3 (es) | 2010-02-24 | 2016-03-08 | Arrowhead Research Corporation | Composiciones para el suministro dirigido de ARNip |
AU2011299233B2 (en) * | 2010-09-07 | 2016-09-15 | Integrated Dna Technologies, Inc. | Modifications for antisense compounds |
US8501930B2 (en) | 2010-12-17 | 2013-08-06 | Arrowhead Madison Inc. | Peptide-based in vivo siRNA delivery system |
CA3131967A1 (en) | 2010-12-29 | 2012-07-05 | F. Hoffman-La Roche Ag | Small molecule conjugates for intracellular delivery of nucleic acids |
EP3597750B1 (en) | 2011-06-23 | 2022-05-04 | Alnylam Pharmaceuticals, Inc. | Serpina1 sirnas: compositions of matter and methods of treatment |
US9340784B2 (en) | 2012-03-19 | 2016-05-17 | Ionis Pharmaceuticals, Inc. | Methods and compositions for modulating alpha-1-antitrypsin expression |
UY35582A (es) | 2013-05-22 | 2014-10-31 | Alnylam Pharmaceuticals Inc | COMPOSICIONES DE ARNi DE SERPINA1 Y SUS MÉTODOS DE USO |
WO2014197524A2 (en) | 2013-06-06 | 2014-12-11 | Serpin Pharma, Llc | Peptide therapy for treatment of alpha-1 antitrypsin deficiency and associated pathologies |
CA2916499A1 (en) * | 2013-07-03 | 2015-01-08 | Dicerna Pharmaceuticals, Inc. | Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded rna |
TW201620526A (zh) * | 2014-06-17 | 2016-06-16 | 愛羅海德研究公司 | 用於抑制α-1抗胰蛋白酶基因表現之組合物及方法 |
-
2015
- 2015-06-10 TW TW104118826A patent/TW201620526A/zh unknown
- 2015-06-15 AR ARP150101897A patent/AR100840A1/es unknown
- 2015-06-16 EA EA201692318A patent/EA201692318A1/ru unknown
- 2015-06-16 CA CA3219720A patent/CA3219720A1/en active Pending
- 2015-06-16 AU AU2015277376A patent/AU2015277376B2/en active Active
- 2015-06-16 CA CA2951700A patent/CA2951700C/en active Active
- 2015-06-16 BR BR112016029781A patent/BR112016029781A2/pt not_active IP Right Cessation
- 2015-06-16 WO PCT/US2015/035976 patent/WO2015195628A2/en active Application Filing
- 2015-06-16 EP EP15809171.0A patent/EP3157541A4/en active Pending
- 2015-06-16 CN CN201580032508.2A patent/CN106535917B/zh active Active
- 2015-06-16 MX MX2016015870A patent/MX2016015870A/es active IP Right Grant
- 2015-06-16 US US14/740,307 patent/US10006025B2/en active Active
- 2015-06-16 CN CN202110660130.8A patent/CN113444725A/zh active Pending
-
2016
- 2016-12-01 MX MX2023003672A patent/MX2023003672A/es unknown
- 2016-12-01 MX MX2020010524A patent/MX2020010524A/es unknown
- 2016-12-15 IL IL249597A patent/IL249597A0/en unknown
-
2017
- 2017-06-16 HK HK17106007.9A patent/HK1232163A1/zh unknown
-
2018
- 2018-05-25 US US15/990,330 patent/US20180258430A1/en not_active Abandoned
-
2019
- 2019-05-31 US US16/428,431 patent/US11384355B2/en active Active
-
2021
- 2021-06-28 AU AU2021204399A patent/AU2021204399A1/en active Pending
-
2022
- 2022-06-08 US US17/834,988 patent/US20230002768A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AR100840A1 (es) | 2016-11-02 |
CA3219720A1 (en) | 2015-12-23 |
TW201620526A (zh) | 2016-06-16 |
US20190284558A1 (en) | 2019-09-19 |
BR112016029781A2 (pt) | 2017-10-31 |
US20180258430A1 (en) | 2018-09-13 |
EP3157541A2 (en) | 2017-04-26 |
EA201692318A1 (ru) | 2017-06-30 |
CN113444725A (zh) | 2021-09-28 |
MX2023003672A (es) | 2023-04-18 |
WO2015195628A2 (en) | 2015-12-23 |
CA2951700C (en) | 2024-01-02 |
US20230002768A1 (en) | 2023-01-05 |
AU2015277376B2 (en) | 2021-04-01 |
MX2016015870A (es) | 2017-04-27 |
US20150361427A1 (en) | 2015-12-17 |
IL249597A0 (en) | 2017-02-28 |
AU2021204399A1 (en) | 2021-07-22 |
CN106535917B (zh) | 2021-07-06 |
US11384355B2 (en) | 2022-07-12 |
CA2951700A1 (en) | 2015-12-23 |
MX2020010524A (es) | 2020-11-06 |
AU2015277376A1 (en) | 2016-12-08 |
EP3157541A4 (en) | 2018-04-04 |
US10006025B2 (en) | 2018-06-26 |
CN106535917A (zh) | 2017-03-22 |
WO2015195628A3 (en) | 2016-02-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL290566A (en) | Preparations and methods for preventing lipoprotein A gene expression | |
HK1232163A1 (zh) | 用於抑制α- 抗胰蛋白酶基因表達的組合物及方法 | |
HRP20181630T1 (hr) | Postupci i kompoziti za ciljne genetske modifikacije i načini korištenja | |
IL273875A (en) | Methods and compounds for inhibiting expression of LDHA | |
IL254518A0 (en) | Preparations and methods for suppressing the expression of the factor xii gene | |
HK1252852A1 (zh) | 阻止HIF2α基因表達的組合物及方法 | |
IL282747A (en) | Preparations and methods for inhibiting expression of the ALAS1 gene | |
EP3105327A4 (en) | Compositions and methods of using microrna inhibitors | |
EP3237619B8 (en) | Compositions and methods for inhibiting expression of adamts-5 and adam17 |